Loading stock data…
Jazz Pharmaceuticals plc identifies (JAZZ)
$230.02+3.82 (+1.69%)
Market ClosedLast close Jun 26
Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Jazz Pharmaceuticals plc in the Healthcare sector is trading at $230.02 with a market capitalization of $14.3B. Wall Street consensus targets $257.00 (19 analysts), implying a +11.7% move over the next 12 months. The stock is currently near its 52-week high of $243.32, remaining 29.6% above its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality. The Whystock Score of 100/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +11.7% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $1.07B↓ | $1.20B↑ | $1.13B↑ | $1.05B↑ | $897.80M |
| Gross Profit | $934.80M↓ | $1.04B↑ | $997.23M↑ | $929.44M↑ | $793.20M |
| Operating Income | $336.60M↑ | $254.53M↑ | $100.01M↓ | $218.97M↑ | -$55.90M |
| Net Income | $293.10M↑ | $203.45M↓ | $251.41M↑ | -$718.47M↓ | -$92.50M |
Peer Comparison
JNJUNHPFE
Fundamentals
Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally. The company offers Xywav to treat cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopat...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$14.33B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
0.65%
Volume
Today's trading volume
515,153
Recent News
Why Did SLS, MRNA, ABCL Stocks Surge To 52-Week Highs Last Week?
Investor interest has focused on companies nearing key milestones, signing major partnerships, or improving their business outlook.
ABCELLERA BIOLG (ABCL) Surges 7.1%: Is This an Indication of Further Gains?
ABCELLERA BIOLG (ABCL) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Jazz Pharmaceuticals (JAZZ) Stock Gets Fair Value Boost As Ziihera Views Split Analysts
The central analyst fair value estimate for Jazz Pharmaceuticals has shifted from US$225.53 to US$257.00, indicating that a higher price target is being used in many current models. That change is closely tied to fresh debate over how much Ziihera, the oncology pipeline and the Xywav neurology franchise can contribute to long term earnings, with bullish and bearish analysts reaching very different conclusions. As you read on, you will see how to track these moving pieces and what to monitor...
Jazz Pharmaceuticals (JAZZ) Expands AbCellera Tie Up As Zepzelca Trial Misses Goal
Jazz Pharmaceuticals (NasdaqGS:JAZZ) expanded its collaboration with AbCellera Biologics to develop next-generation T-cell multispecific antibodies for gastrointestinal and other solid tumors. The company reported top-line results from the Phase 3 LAGOON trial of Zepzelca in second-line small cell lung cancer, which did not meet its primary endpoint. Zepzelca continues to have its first-line approval based on prior studies, and Jazz Pharmaceuticals is in discussions with the FDA about future...
Jazz Pharmaceuticals and AbCellera Biologics Inc. (ABCL) Announce Collaboration
AbCellera Biologics Inc. (NASDAQ:ABCL) is among the Best Pharmaceutical Stocks. On June 17, 2026, AbCellera Biologics Inc. (NASDAQ:ABCL) and Jazz Pharmaceuticals entered a preclinical research collaboration, option, and license agreement. The deal is to discover and develop next-generation T-cell multispecific antibodies targeting gastrointestinal cancers and other solid tumors. The companies said the partnership includes $56 million […]